The KRAS mutation is not responsible for all cases of resistance to anti-epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC), and new predictive and prognostic factors are actively being sought.
Inno, A., Di Salvatore, M., Cenci, T., Martini, M., Orlandi, A., Strippoli, A., Ferrara, A. M., Bagala', C., Cassano, A., Larocca, L. M., Barone, C. A., Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?, <<CLINICAL COLORECTAL CANCER>>, 2011; 10 (4): 325-332. [doi:10.1016/j.clcc.2011.03.028] [http://hdl.handle.net/10807/25735]
Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?
Inno, Alessandro;Di Salvatore, Mariantonietta;Cenci, Tonia;Martini, Maurizio;Orlandi, Armando;Strippoli, Antonia;Ferrara, Anna Maria;Bagala', Cinzia;Cassano, Alessandra;Larocca, Luigi Maria;Barone, Carlo Antonio
2011
Abstract
The KRAS mutation is not responsible for all cases of resistance to anti-epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC), and new predictive and prognostic factors are actively being sought.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
